GeneDx (WGS) Projected to Post Quarterly Earnings on Tuesday

GeneDx (NASDAQ:WGS - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Tuesday, July 29th. Analysts expect GeneDx to post earnings of $0.09 per share and revenue of $86.00 million for the quarter. GeneDx has set its FY 2025 guidance at EPS.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.17. GeneDx had a negative net margin of 11.69% and a positive return on equity of 10.17%. The firm had revenue of $87.12 million during the quarter, compared to analysts' expectations of $79.90 million. On average, analysts expect GeneDx to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

GeneDx Trading Up 0.6%

WGS stock traded up $0.50 during trading on Friday, hitting $81.95. The company had a trading volume of 104,679 shares, compared to its average volume of 1,059,725. The company has a quick ratio of 3.07, a current ratio of 3.25 and a debt-to-equity ratio of 0.20. The firm has a 50-day moving average price of $77.11 and a 200-day moving average price of $82.78. GeneDx has a 12 month low of $25.32 and a 12 month high of $117.75. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -58.12 and a beta of 2.01.

Insider Activity

In related news, CFO Kevin Feeley sold 5,278 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $93.00, for a total value of $490,854.00. Following the completion of the sale, the chief financial officer directly owned 3,392 shares in the company, valued at approximately $315,456. The trade was a 60.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Katherine Stueland sold 3,220 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $93.00, for a total value of $299,460.00. Following the completion of the sale, the chief executive officer owned 1,720 shares of the company's stock, valued at approximately $159,960. This trade represents a 65.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,411 shares of company stock worth $2,104,828. Corporate insiders own 29.60% of the company's stock.

Institutional Trading of GeneDx

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC grew its stake in shares of GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company's stock worth $240,000 after purchasing an additional 2,707 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company's stock worth $677,000 after purchasing an additional 453 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of GeneDx by 67.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company's stock worth $2,500,000 after purchasing an additional 11,375 shares during the last quarter. Finally, Royal Bank of Canada grew its stake in shares of GeneDx by 30.2% in the first quarter. Royal Bank of Canada now owns 29,479 shares of the company's stock worth $2,611,000 after purchasing an additional 6,840 shares during the last quarter. Institutional investors own 61.72% of the company's stock.

Analyst Ratings Changes

Several research firms recently weighed in on WGS. Jefferies Financial Group upgraded shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a research report on Friday, May 9th. Guggenheim reiterated a "buy" rating and set a $115.00 target price (up previously from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Wells Fargo & Company cut their price target on GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Piper Sandler started coverage on GeneDx in a report on Wednesday, July 9th. They issued an "overweight" rating and a $110.00 price target on the stock. Finally, Wall Street Zen lowered GeneDx from a "buy" rating to a "hold" rating in a report on Sunday, July 13th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $92.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.